Aligning with our findings, other studies have indicated that trans-ferulic acid could be developed as a potential therapy for multiple diseases, including cardiovascular disorders, Alzheimer’s disease, and diabetes mellitus, and it has a protective effect on the intestinal epithelial barrier by enhancing the expression of tight junction (TJ) proteins, including claudin-1, occludin, and ZO-1, in intestinal epithelial cells [40,41,42,43,44]. Here, OCLN is linked to early-onset autosomal dominant Alzheimer disease.